A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.
Michael D Tarantino, James B Bussel, Eun-Ju Lee...
https://pubmed.ncbi.nlm.nih.gov/37339869/Actively Recruiting
Led by Al-Mustansiriyah University · Updated on 2025-08-21
25
Participants Needed
1
Research Sites
52 weeks
Total Duration
This research aims to explore the safety and effectiveness of a modified lower starting dose of avatrombopag in adults with primary immune thrombocytopenia ITP who need second-line treatment. Avatrombopag, an oral medication that stimulates platelet production, is usually started at 20 mg daily, but this study investigates starting at 20 mg every other day to reduce the common issue of platelet count overshoot. The study is an open-label, single-center pilot trial sponsored by Al-Mustansiriyah University. Participants will begin treatment with avatrombopag 20 mg every other day for one week, followed by dose adjustments based on platelet counts. The study includes three phases dose adjustment, maintenance, and dose tapering with follow-up, lasting up to 24 weeks of treatment. The goal is to assess the response to this lower starting dose and monitor safety, including bleeding complications and quality of life changes. Throughout the study, participants will have platelet levels and other health measures monitored regularly. Researchers will evaluate how quickly and effectively platelet counts respond, the rates of overshoot and treatment failure, and sustained response after stopping treatment at week 52. Safety and quality of life will also be tracked over the year. Overall participation may last up to 52 weeks, including treatment and follow-up phases.
CONDITIONS
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
A
Alaa Alwan, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Al-Mustansiriyah University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants start avatrombopag 20 mg every other day for one week, followed by dose adjustments based on platelet count, continuing treatment for a total of 6 months.
Regular visits for dose adjustment and monitoring during treatment
Duration - Up to 6 months after treatment
Participants are monitored for safety, bleeding complications, and sustained response off-treatment after completing avatrombopag treatment.
Periodic visits up to week 52
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Michael D Tarantino, James B Bussel, Eun-Ju Lee...
https://pubmed.ncbi.nlm.nih.gov/37339869/Drew Provan, Donald M Arnold, James B Bussel...
https://pubmed.ncbi.nlm.nih.gov/31770441/Hiroki Yamaguchi, Masaki Iino, Shugo Kowata...
https://pubmed.ncbi.nlm.nih.gov/40392465/Cristina Pascual-Izquierdo, Blanca Sánchez-González, Mariana-Isabel Canaro-Hirnyk...
https://pubmed.ncbi.nlm.nih.gov/39394928/Waleed Ghanima, Bertrand Godeau, Douglas B Cines...
https://pubmed.ncbi.nlm.nih.gov/22740443/Heng Mei, Hu Zhou, Ming Hou...
https://pubmed.ncbi.nlm.nih.gov/37700877/Francesco Rodeghiero, Roberto Stasi, Terry Gernsheimer...
https://pubmed.ncbi.nlm.nih.gov/19005182/Zain M Virk, Rebecca K Leaf, David J Kuter...
https://pubmed.ncbi.nlm.nih.gov/38063420/Axel Matzdorff, Sonja R Alesci, Johanna Gebhart...
https://pubmed.ncbi.nlm.nih.gov/36787705/Wojciech Jurczak, Krzysztof Chojnowski, Jiří Mayer...
https://pubmed.ncbi.nlm.nih.gov/30191972/Al-Mustansiriyah University
Lead Sponsor